CenterBook Partners’s Starling Oncology STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,241,660
Closed -$6.74M – 1030
2026
Q2
$6.74M Sell
1,241,660
-326,763
-21% -$1.37M 0.33% 69
2026
Q1
$4.82M Sell
1,568,423
-1,460,889
-48% -$4.48M 0.26% 106
2025
Q4
$10.8M Buy
3,029,312
+324,662
+12% +$1.2M 0.53% 38
2025
Q3
$9.44M Buy
2,704,650
+1,988,751
+278% +$6.81M 0.47% 44
2025
Q2
$1.47M Buy
+715,899
New +$1.79M 0.08% 280

Other funds holding STLN

CenterBook Partners's STLN Position: Q3 2026 in Review

CenterBook Partners sold out of Starling Oncology (STLN) in Q3 2026, closing a stake of 1,241,660 shares — an estimated $6.74M sold.

CenterBook Partners first reported a position in STLN in Q2 2025 and held it in 5 quarters. The position peaked at $10.8M in Q4 2025. 25 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • CenterBook Partners reported no remaining Starling Oncology position as of Q3 2026 after selling out during the quarter.
  • CenterBook Partners sold 1,241,660 Starling Oncology shares in Q3 2026, an estimated $6.74M.
  • CenterBook Partners first reported a position in Starling Oncology in Q2 2025 and held it in 5 quarters.
  • CenterBook Partners's Starling Oncology position peaked at $10.8M in Q4 2025.
  • 25 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.